Phaseline

Companies › Nacuity Pharmaceuticals

Nacuity Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Ophthalmology, Metabolic and endocrine; next expected readout Apr 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
N-Acetylcysteine Amide (NPI-001)
Cystine-depleting agent; reduces intracellular cystine accumulation
–Phase 3Retinitis Pigmentosa (RP); CystinosisApr 2029
NPI-002 Intravitreal Implant
Intravitreal implant for cataract progression delay
–Phase 1Cataract–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05994534N-Acetylcysteine Amide (NPI-001)Phase 1CystinosisMetabolic and endocrineMay 2026
NCT05026632NPI-002 Intravitreal ImplantPhase 1CataractOphthalmologySep 2026
NCT07710196N-Acetylcysteine Amide (NPI-001)Phase 3Retinitis Pigmentosa (RP)OphthalmologyApr 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Biojiva Bausch & Lomb Huons Sling Therapeutics PolyActiva

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.